SSRP1 and mature T-cell and NK-cell non-Hodgkin lymphoma: Our work provides a rationale for initiating clinical studies on SSRP1 inhibitors quinacrine/CBL0137 in PTCL and outlines a new combination epigenetic therapy that shows promise for the treatment of genetically heterogeneous PTCL.